Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Active:	Yes
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT05445778
Trial Phases:	Phase III	Protocol IDs:	IMGN853-0421 (primary) NCI-2023-00369
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Abbvie
NCI Full Details:	http://clinicaltrials.gov/show/NCT05445778

Summary

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and
efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in
participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube
cancers with high folate receptor-alpha (FRa) expression.

Objectives

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed
to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by
delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein
called folate receptor alpha (FRa). It is being developed as maintenance therapy for the
treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian,
primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Patients must have confirmation of FRa positivity by the Ventana FOLR1 Assay.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.